3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
2
Terminated
1
Sponsor Class
OTHER
8
INDUSTRY
3
NIH
1
Study Type
Observational
2
Interventional
1
Sponsor
Cancer Type
Breast
2
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
604
Carboplatin
374
Paclitaxel
283
Cisplatin
270
Gemcitabine
252
Pemetrexed
194
Bevacizumab
191
Docetaxel
186
Nivolumab
180
Injections
169
Cyclophosphamide
150
atezolizumab
139
Fluorouracil
134
Capecitabine
133
Oxaliplatin
132
Dexamethasone
128
durvalumab
113
Fulvestrant
113
130-nm albumin-bound paclitaxel
110
fludarabine
103
Cetuximab
100
Leucovorin
97
Rituximab
95
venetoclax
90
Lenalidomide
83
enzalutamide
77
Prednisone
77
Azacitidine
74
Irinotecan
73
Doxorubicin
72
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
INDUSTRY
×
Biopsy, Large-Core Needle
×
1 year
×
Clear all
NCT03524430
2026-05-28
BREVITY
Rna Diagnostics Inc.
Phase NA
Active not recruiting
801 enrolled
NCT05520099
2026-04-29
ELEPHAS-02
Elephas
Active not recruiting
416 enrolled
NCT05435352
2025-07-30
PEAR-TNBC
Ourotech, Inc.
Terminated
34 enrolled